VCEL Vericel Corporation

NASDAQ
$39.71

Vericel Corporation (VCEL) is expected to report earnings on November 9, 2026, before the market open. The consensus earnings estimate is $0.02 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -18.8% since its last earnings release on July 30, 2026.

Vericel Beat Consensus Estimates, Raises Guidance, but Remains In-line with Estimates
Thursday, July 30, 2026 · 7:55 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 7:55 AM ET
Earnings Whisper
-
vs $0.02
Rev est $78.3M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $42.17

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Vericel Corporation

Vericel Corp is engaged in the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two cell therapy products including Carticel and Epicel.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.